Comprehensive Therapeutic Dossier for the SD Biocare BioS PB™ Spore Line
1. Modern Paradigm: Expanding Clinical Indications
Precision probiotics have moved far beyond basic gut regularity. Through advanced multi-omics profiling, spore-forming biotherapeutics are now deployed to target systemic metabolic disorders, gut-brain axis dysregulation, dermatological inflammatory conditions, and localized immune barrier breakdown.
Figure 1: Efficacy Mapping of BioS PB™ Strains Across Clinical Indications
2. Comprehensive Clinical Indication Matrix
| BioS PB™ Strain | Clinical Axis / Indication | Target Mechanism & Physiological Pathway |
|---|---|---|
| BioS PB-Coagulans (B. coagulans) | IBS & Functional Bloating | L(+) lactic acid production reduces luminal pH, suppressing gas-producing pathogens and accelerating gastric emptying. |
| BioS PB-Coagulans (B. coagulans) | Metabolic Health & Insulin Resistance | Modulates SCFA ratios (acetate/propionate), activating GLP-1 secretion and lowering systemic low-grade C-reactive protein (CRP). |
| BioS PB-Coagulans (B. coagulans) | Gut-Brain & Stress Response | Attenuates cortisol response via the vagus nerve and promotes short-chain fatty acid stimulation of central neurotransmitters. |
| BioS PB-Subtilis (B. subtilis) | Small Intestinal Bacterial Overgrowth (SIBO) | Produces antimicrobial peptidase (surfactin) to inhibit opportunistic pathogen overgrowth in the upper GI tract. |
| BioS PB-Subtilis (B. subtilis) | Macronutrient Malabsorption | Secretes robust bio-available enzymes (proteases, amylases, lipase) to enhance protein breakdown and micronutrient bioavailability. |
| BioS PB-Subtilis (B. subtilis) | Gut Barrier Integrity (‘Leaky Gut’) | Up-regulates expression of tight-junction proteins (Claudin-1, Occludin), reducing lipopolysaccharide (LPS) translocation. |
| BioS PB-Clausii (B. clausii) | Post-Antibiotic Dysbiosis | Intrinsic resistance to major antibiotic classes allows simultaneous colonization to prevent Opportunistic Infections (e.g., C. difficile). |
| BioS PB-Clausii (B. clausii) | Mucosal & Systemic Immunity | Stimulates local Secretory IgA (sIgA) synthesis and modulates IL-10 / TNF-alpha cytokine equilibrium in intestinal mucosa. |
| BioS PB-Clausii (B. clausii) | Dermatological Gut-Skin Axis | Reduces systemic endotoxemia contributing to acne, eczema, and cutaneous inflammatory flare-ups. |
3. Strategic Formulation Stacking
By combining strains with distinct physiological targets, clinicians can design comprehensive biotherapeutic regimens:
• Metabolic & Inflammatory Regimen: Combine BioS PB-Coagulans + BioS PB-Subtilis to suppress CRP levels, reduce systemic LPS burden, and improve postprandial glucose stability.
• Immune Barrier & Microbiome Recovery: Combine BioS PB-Clausii + BioS PB-Subtilis during antibiotic treatments to preserve sIgA defenses and maintain tight-junction seal integrity.
• Gut-Skin-Brain Axis Optimization: Combine BioS PB-Coagulans + BioS PB-Clausii for patients presenting concurrent IBS symptoms, anxiety, and cutaneous inflammation.
.svg)